00:51 , Jun 7, 2019 |  BC Innovations  |  Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
00:00 , May 17, 2019 |  BC Innovations  |  Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for...
23:07 , Mar 20, 2019 |  BioCentury  |  Finance

Flagship prepares for scale

With its newly closed $824 million Special Opportunities Fund II, Flagship Pioneering has deepened its pool of capital to invest in its portfolio companies as they seek to scale up with multiproduct platforms. Upon the...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
20:13 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

Moderna Inc. (NASDAQ:MRNA) tumbled out of the gate on Dec. 7, losing $4.40 (19%) to $18.60 in its trading debut for a loss of $1.4 billion in market cap as U.S. stocks across the board...
15:59 , Nov 16, 2018 |  BC Week In Review  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed on Nov. 9 to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship...
01:39 , Nov 10, 2018 |  BC Extra  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship Pioneering launched Moderna...
22:22 , Nov 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
23:02 , Oct 25, 2018 |  BC Innovations  |  Emerging Company Profile

Strand’s smart mRNA

Strand Therapeutics Inc. has developed a method to apply pharmacological control to therapeutic mRNA, enabling the company to regulate when, where and how potently mRNA transcripts are expressed using small molecules. Its initial focus is...
18:41 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic; neurology

INDICATION: Porphyria; pain Mouse, rabbit and monkey studies suggest a lipid nanoparticle (LNP)-encapsulated mRNA encoding HMBS could help treat acute intermittent porphyria (AIP), which is caused by hepatic HMBS deficiency, and AIP-associated pain. In mouse...